1. Home
  2. SPCB vs MAIA Comparison

SPCB vs MAIA Comparison

Compare SPCB & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SuperCom Ltd. (Israel)

SPCB

SuperCom Ltd. (Israel)

HOLD

Current Price

$8.70

Market Cap

45.3M

Sector

Technology

ML Signal

HOLD

Logo MAIA Biotechnology Inc.

MAIA

MAIA Biotechnology Inc.

HOLD

Current Price

$2.08

Market Cap

49.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SPCB
MAIA
Founded
1988
2018
Country
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
45.3M
49.3M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
SPCB
MAIA
Price
$8.70
$2.08
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
88.8K
1.2M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$27.13
N/A
P/E Ratio
$10.36
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.06
$0.87
52 Week High
$13.69
$3.19

Technical Indicators

Market Signals
Indicator
SPCB
MAIA
Relative Strength Index (RSI) 48.90 53.42
Support Level $7.88 $1.83
Resistance Level $8.95 $2.03
Average True Range (ATR) 0.65 0.23
MACD -0.01 -0.05
Stochastic Oscillator 28.28 36.45

Price Performance

Historical Comparison
SPCB
MAIA

About SPCB SuperCom Ltd. (Israel)

SuperCom Ltd is an Israel-based provider of traditional and digital identity solutions, providing safety, identification, tracking, and security products to governments and organizations. The company comprises three main Strategic Business Units: e-Gov; IoT, which is the key revenue driver; and Cyber Security. The Company's IoT products and solutions reliably identify, track and monitor people or objects in real time, enabling the customers to detect unauthorized movement of people, vehicles and other monitored objects. The geographical segments of the company include Africa, European countries, South America, the United States, Israel, and APAC.

About MAIA MAIA Biotechnology Inc.

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.

Share on Social Networks: